Sansure Immunological Technology Platform adopts advanced nanoparticle technology, protein labelling and modification technology, using high quality coloured latex and colloidal gold as tracers, and has developed a series of easy-to-use, highly sensitive and rapid detection products, covering SARS-CoV-2 antigen, SARS-CoV-2/InFluA/InFluB antigen, SARS-CoV-2 neutralizing antibody and other SARS-CoV-2 immunological reagents, to meet the needs of different scenarios such as home self-test, POCT and laboratory testing.

Ambassadors of Malawi to China visited Sansure Biotech

Accompanied by the management from Office of Foreign Affairs Commission of CPC Hunan Provincial Committee, H.E. Allan Chintedza, the Ambassador of Malawi to China, and Oliver Kingstone Chimphambano, the Deputy Ambassador of Malawi to China, visited Sansure Biotech on June 23rd. Dr. Lizhong Dai, the Chairman of Sansure Biotech was also along with the visit. Ambassador Allan Chintedza visited the […]

British Consul General in Guangzhou visited Sansure Biotech

On June 20, Jo Hawley, the British Consul General in Guangzhou, and Mr. Mike McCourt, Healthcare Director in China for the British Department of International Trade China, visited Sansure Biothech. They were accompanied by the management from Changsha High-Tech Development Zone, along with Dr. Lizhong Dai, the Chairman of Sansure. During the visit, they had an in-depth discussion on further […]

Sansure Obtains CE Mark under IVDR Certification for New POCT iPonatic S-Q36A

On June 7, the new generation of iPonatic full-automatic nucleic acid testing and analysis system of Sansure Biotech was certified by IVDR CE, which will better serve the construction of public health prevention and control system globally. CE certification is mandatory for product access to the EU market. From May 26, 2022, the EU comprehensively implemented in vitro diagnosis medical […]

Focusing on Screening and early detection of cancer, Sansure Biotech and Singlera Genomics have reached a strategic cooperation

On June 8, Singlera Genomics (Shanghai) Ltd. (hereinafter referred to as “Singlera Genomics”) announced that it had completed a 300 million yuan B+ round of financing. This round of financing is led by Forestone Capital, followed by funds from Yinhe Yuanhui, Guojing Capital, Junci Investment, Qiandao Investment, Best, Brilliance Investment. As a strategic investor, Sansure Biotech followed the investment, and […]

Sansure Biotech Inc. Annual Report 2021: Prosperous in All Aspects

Sansure Biotech Inc. released its 2021 annual report and 2022 Q1 report. Under the severe challenge of the COVID-19 pandemic, the company independently developed various products and achieved brilliant achievements. This report summarizes Sansure’s 2021 achievements, including revenue, R&D priorities, and significant future direction. Sansure maintains a leading position in the medical industry, with stable revenue and strong resilience. In […]

Get in touch with us
I confirm that I have reviewed Sansure's Privacy Policy and agree with the collection and storage of my personal data.

Thank you!

We shall contact you soon!
Back Top